News

Novartis announced results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with…
Read More...

BiomX Ltd., a microbiome company developing both natural and engineered phage therapies, announced completion of construction of a new state-of-the-art manufacturing facility. The new…
Read More...

LabCorp announced that its Covance Drug Development business has launched a laboratory solution within its functional service provider (FSPx) offering. Covance has been offering FSP…
Read More...

Novartis announced full results from its global Phase III PARAGON-HF study, investigating the efficacy and safety of Entresto (sacubitril/valsartan) versus the active comparator…
Read More...

Ajinomoto Bio-Pharma Services announced its intention to purchase the remaining 50 percent ownership interest in its Visakhapatnam, India joint venture, Granules OmniChem Private…
Read More...

Roche announced that the European Commission has approved Tecentriq (atezolizumab) plus chemotherapy (Abraxane ) for the treatment of adult patients with unresectable locally advanced…
Read More...

AstraZeneca announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint,…
Read More...

AbbVie announced that MERU, a Phase 3 trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit at a…
Read More...

Esperion announced positive top-line results from the Phase 2 bempedoic acid / ezetimibe combination tablet study (1002-058). This was a randomized, double-blind, parallel group study…
Read More...

La Jolla Pharmaceutical Company, a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering…
Read More...

PCI Pharma Services (PCI) has solidified its leadership position in the EU with strategic investment to deepen its presence in Ireland and expand its European foothold. PCI has…
Read More...

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced that Immatics…
Read More...

HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, announced the completion of a $67 Million…
Read More...

AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis…
Read More...

Lannett Company announced that it has entered into an agreement with Sinotherapeutics Inc., a China-based specialty pharmaceutical company, to be the exclusive U.S. distributor of…
Read More...

Viralgen and AskBio announced that Viralgen has received Current Good Manufacturing Practices (cGMP) compliance accreditation and Pharmaceutical Laboratory authorization by the AEMPS…
Read More...

Ionis Pharmaceuticals, the leader in RNA-targeted therapeutics, announced today that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B…
Read More...

Alvotech and Prestige Biopharma announced a new contract manufacturing partnership for one of Prestige Biopharma´s biosimilar candidates. Alvotech’s Contract Services have been…
Read More...

Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, announced that it has obtained a full exclusive license on RAL…
Read More...

Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, and Noile-Immune Biotech, Inc., Tokyo, Japan, a biotechnology company focusing on the development of innovative…
Read More...